5-Azacytidine and decitabine monotherapies of myelodysplastic disorders

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1700-1709

  Kuykendall, Jim R ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

5 aza 2 deoxycytidine; 5 Azacytidine; Decitabine; acute myelogenous leukemia; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BILIRUBIN; CREATININE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; INCIDENCE; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DYSFUNCTION; MALAISE; MALE; MALIGNANT TRANSFORMATION; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RASH; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SEIZURE; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS; DNA MODIFICATION METHYLASES; HUMANS; MEDLINE; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 25844498481     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E612     Document Type: Review

References (96)

1. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
2. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249:135-64.
3. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;7:573-86.
4. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
5. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002;87:1324-41.
6. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002;21:5496-503.
7. Jain PK. Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann N Y Acad Sci 2003;983:71-83.
8. Momparler RL. Cancer epigenetics. Oncogene 2003;22:6479-83.
9. Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J, et al. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs 2003;4:1442-50.
10. Hennessy BT, Garda-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 2003;12:1985-93.
11. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003;109:89-102.
12. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22:6489-96.
13. Chiurazzi P, Neri G. Reactivation of silenced genes and transcriptional therapy. Cytogenet Genome Res 2003;100:56-64.
14. Baylin SB. Reversal of gene silencing as a therapeutic target for cancer-roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp 2004;259:226-33; discussion 234-7, 285-8.
15. Candoni A, Silvestri F, Buonamici S, Li D, Reddy P, Galili N, et al. Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 2004;41(suppl 4):S13-20.
16. Brown R, Plumb JA. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther 2004;4:501-10.
17. Holliday R. A new theory of carcinogenesis. Br J Cancer 1979;40:513-22.
18. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
19. Doerfler W. DNA methylation and gene activity. Ann Rev Biochem 1983;5:93-124.
20. Jones PA. DNA methylation and cancer. Cancer Res 1986;46:461-6.
21. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
22. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
23. Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazur R. FDA drug approval summary: azacytidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005;10:176-82.
24. Christman JK, Price P, Pedrinan L, Acs G. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur J Biochem 1977;81:53-61.
25. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979;17:771-9.
26. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′deoxycytidine. J Biol Chem 1982;257:2041-8.
27. Christman JK, Mendelsohn N, Herzog D, Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 1983;43:763-9.
28. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6.
29. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64:922-9.
30. Momparler RL, Bouchard J, Samson J. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. LeukRes 1985;9:1361-6.
31. Jones PL, Veenstra GL, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit deacetylase to repress transcription. Nat Genet 1998;19:187-91.
32. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG binding protein MECP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
33. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002;13:1699-716.
34. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med 2002;4:1-17. PMID 14987388.
35. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970;30:2760-9.
36. Li LH, Olin EJ, Fraser TJ, Bhryan BK. Phase specificity of 5-azacytidine against mammalian cells in tissue cultura. Cancer Res 1970;30:2770-5.
37. Momparler RL, Samson J, Momparler LF, Rivard GE. Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 1984;13:191-4.
38. Weiss JW, Pitot HC. Inhibition of ribosomal ribonucleic acid maturation by 5-azacytidine and 8-azaguanine in Novikoff hepatoma cells. Arch Biochem Biophys 1974;160:119-29.
39. Cihak A, Weiss JW, Pitot HC. Characterization of polyribosomes and maturation of ribosomal RNA in hepatoma cells treated with 5-azacytidine. Cancer Res 1974;34:3003-9.
40. Momparler RL, Siegel S, Avilla F, Lee T, Karon M. Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. Biochem Pharmacol 1976;25:389-92.
41. Lee TT, Karon MR. Inhibition of protein synthesis in 5-aza-cytidine- treated HeLa cells. Biochem Pharmacol 1976;25:1737-42.
42. Lu LW, Chiang GH, Medina D, Randerath K. Drug effects on nucleic acid modification. 1. A specific effect of 5-azacytidine on mammalian transfer RNA methylation in vivo. Biochem Biophys Res Commun 1976;68:1094-101.
43. Momparler RL, Goodman J. In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res 1977;37:1636-9.
44. Lu LJ, Randerath K. Mechanism of 5-azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency. Cancer Res 1980;40:2701-5.
45. Glazer RI, Peale AL, Beisler JA, Abbasi MM. The effect of 5-azacytidine and dihydro-5-azacytidine on nuclear ribosomal RNA and poly(A) RNA synthesis in L1210 cells in vitro. Mol Pharmacol 1980;17:111-7.
46. Lloyd HH, Dulmadge EA, Wilkoff LJ. Kinetics of the reduction in viability of cultured L1220 leukemia cells exposed to 5-azacytidine. Cancer Chemother Rep 1972;56:585-91.
47. Attadia V. Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937, Leukemia 1993;7(suppl 1):S9-16.
48. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983;33:9-10.
49. Bouchard J, Momparler RL. Incorporation of 5-aza-2′-deoxycytidine- 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol 1983;24:109-14.
50. Jutterman R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA methylation. Proc Natl Acad Sci U S A 1994;91:11797-801.
51. Strathdee G, Brown R. Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 2002;11:747-54.
52. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997;90:1403-9.
53. Uchida T, Kinoshita T, Ohno T, Ohashi H, Nagai H, Saito H. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001;15:157-65.
54. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64.
55. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-40.
56. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
57. Dowell JE, Minna JD. Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes. J Clin Oncol 2004;1353-5.
58. Momparler RL, Derse D. Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 1979;28: 1443-4.
59. Beauséjour CM, Gagnon J, Primeau M, Momparler RL. Cytotoxicity activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′- deoxycyctidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 2002;293:1478-84.
60. Momparler RL. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 1985;30:287-99.
61. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin KT, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1982;5:453-62.
62. Raza A, Preisler HD, Day R, Yasin Z, White M, Lykins J, et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood 1990;76:2191-7.
63. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot Phase I-II study of 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-68.
64. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol Ther 1986;30:277-86.
65. Momparler RL, Laliberte J. Induction of cytidine deaminase in HL-60 myeloid leukemia cells by 5-aza-2′-deoxycytidine. Leuk Res 1990;14: 751-4.
66. Beauséjour CM, Eliopoulos N, Momparler L, Le NL, Momparler RL. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human deaminase gene. Cancer Gene Ther 2001;8: 669-76.
67. Israili ZH, Vogler WR, Mingioli ES, Pirkle JL, Smithwick RW, Golstein JH. The deposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976;36:1453-61.
68. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-cytidine-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6.
69. Bennett JM, Catovsky D, Daniel MY, Fladrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
70. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
71. Aul C, Gatterman N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 1995;16:247-62.
72. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 1998;22(suppl):S17-21.
73. List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002;7(suppl):S39-49.
74. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology 2003; Hematology (Am Soc Hematol Educ Program):176-99.
75. Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, et al. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993;7(suppl 1):S36-41.
76. Zagonel V, Giovanni LR, Maaotta G, Babare R, Sardeo G, Gattie V, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavorable myelodysplastic syndromes. Leukemia 1993;7(suppl 1):30-5.
77. Wijermans PW, Krudler JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5.
78. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
79. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;10:2429-40.
80. Kornblith A, Herndon J, Silverman L, Demakos E, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;10:2241-52.
81. Issa JP, Garcia-Manero G, Giles F, Mannari R, Thomas D, Faderl S, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
82. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004; 28:785-90.
83. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(suppl):S21-9.
84. Silverman LR, Holland JF, Demakos E. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921 (abstract). Ann Hematol 1994;68:A12.
85. Kantarjian H. Treatment of myelodysplastic syndrome: questions raised by the azacytidine experience. J Clin Oncol 2002;10:2415-6.
86. Package insert. Vidaza (azacytidine for injection). Boulder, CO: Pharmion Corporation, edited 2004 Aug 31.
87. Carr BI, Reilly JC, Smith SS, Winberg C, Riggs A. The tumorgenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis 1984;5:1583-90.
88. Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer 1988;57:395-402.
89. Landolph JR, Jones PA. Mutagenicity of 5-azacytidine and related nucleosides in C3H10T1/2 clone 8 and V79 cells. Cancer Res 1982;42:817-23.
90. Schmahl W, Torok P, Kriegel H. Embryotoxicity of 5-azacytidine in mice. Phase- and dose-specificity studies. Arch Toxicol 1984;55:143-7.
91. Rosen MB, House HS, Francis BM, Chernoff N. Teratogenicity of 5-azacytidine in the Sprague-Dawley rat. J Toxicol Environ Health 1990;29:201-10.
92. Cummings AM. Effect of 5-azacytidine administration during very early pregnancy. Fundam Appl Toxicol 1994;23:429-33.
93. Branch S, Francis BM, Brownie CF, Chernoff N. Teratogenic effects of the demethylating agent 5-aza-2′-deoxycytidine in the Swiss Webster mouse. Toxicology 1996;112:37-43.
94. SuperGen. SuperGen receives patent notice of allowance for claims relating to Dacogen (decitabine) as part of combination therapy for treatment of multiple cancer types. Media release: 7 Jul 2003. www.supergen.com (accessed 2005 Aug 29).
95. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidine (decitabine), a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34(suppl):S111-5.
96. Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-84.